Acomhal

Acomhal Nanotechnologies is a Spanish biotechnology company dedicated to the development of novel therapies targeting cancer stem cells (CSCs) to prevent tumor recurrence and metastasis. The company's core technology is based on a cell-penetrating peptide that disrupts the interaction between Connexin 43 and c-Src, a critical pathway for the survival and chemoresistance of CSCs in aggressive tumors. Their lead candidate is currently being evaluated for the treatment of glioblastoma and triple-negative breast cancer. By specifically targeting the niche of cells responsible for relapse, Acomhal aims to provide a transformative approach to oncology that complements existing standard-of-care treatments.